Every material Form 8-K C4 Therapeutics, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
C4 Therapeutics reported third-quarter 2026 revenue of $8.5 million, down from $11.2 million a year earlier, as research activities tied to its Merck and Merck KGaA collaborations concluded. Net loss narrowed to $21.8 million, or $0.16 per share, from $32.2 million, or $0.44 per share, in the prior-year quarter, which included a $10.7 million impairment charge. The company said its cash runway extends to the end of 2028.
Q3 2026 revenue $8.5 million vs. $11.2 million in Q3 2025, driven by lower Merck and Merck KGaA research revenue, partly offset by Roche collaboration revenue
Q3 2026 net loss $21.8 million ($0.16 per share) vs. $32.2 million ($0.44 per share); Q3 2025 included a $10.7 million impairment of long-lived assets
Cash, cash equivalents and marketable securities were $274.7 million at September 30, 2026, vs. $300.4 million at June 30, 2026
Company expects current cash to fund its operating plan to the end of 2028; Phase 2 MOMENTUM trial enrollment expected to complete in 1Q 2027
C4 Therapeutics presented new biomarker data from its Phase 1 cemsidomide trial with dexamethasone and preliminary data from the first two patients in its Phase 1b trial with elranatamab at the 23rd International Myeloma Society Annual Meeting. The filing also reports that the safety data review committee declared the 75 µg dose level safe in combination with elranatamab, and the trial is advancing to a dose escalation cohort at 100 µg and an expansion cohort at 75 µg. The filing does not include financial results, and the company expects data from all Phase 1b cohorts in mid-2027.
Phase 1 trial with dexamethasone included 62 heavily pre-treated RRMM patients across once-daily dose levels
Biomarker data from the first two Phase 1b patients is based on information as of June 22, 2026
Safety data review committee declared the 75 µg dose safe with elranatamab after a six-patient first safety cohort
Data from all Phase 1b cohorts are expected in mid-2027
C4 Therapeutics reported second-quarter 2026 revenue of $6.6 million, up slightly from $6.5 million a year earlier, and a net loss of $23.6 million, down from $26.0 million. Lower research and development and general and administrative expenses drove the smaller loss, and the company said its cash will fund operations to the end of 2028. Per-share loss fell to $0.18 from $0.37, but the weighted-average share count rose to about 130.7 million from 71.0 million.
Q2 2026 revenue was $6.6 million, versus $6.5 million in Q2 2025, helped by the new Roche collaboration.
R&D expense fell to $24.5 million from $26.2 million; G&A expense fell to $8.6 million from $8.8 million.
Net loss per share was $0.18, compared with $0.37; weighted-average shares rose to 130,696,742 from 71,005,743.
Cash, cash equivalents and marketable securities were $300.4 million at June 30, 2026, which the company expects to fund operations to the end of 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every C4 Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →